Dashboard
Manage Tickers

TRVI Trevi Therapeutics, Inc.

Nasdaq trevitherapeutics.com


$ 10.65 $ -0.24 (-2.2 %)    

Thursday, 23-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.54 $ 5.09 (0.84 %)
DIA $ 467.15 $ 1.51 (0.32 %)
SPY $ 672.13 $ 3.96 (0.59 %)
TLT $ 91.39 $ -0.63 (-0.68 %)
GLD $ 378.58 $ 1.51 (0.4 %)
$ 10.65
$ 10.76
$ 10.21 x 1
$ 11.15 x 2
$ 10.51 - $ 10.90
$ 2.36 - $ 11.11
1,216,273
na
1.3B
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-20-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 06-14-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trevi-therapeutics-announced-two-accepted-abstracts-for-presentation-at-the-chest-2025-annual-meeting-in-chicago-oct-1922-2025
Trevi Therapeutics Announced Two Accepted ...
10/08/2025 11:41:00

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/03/2025 21:05:59

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/09/2025 17:35:29

trevi-therapeutics-option-alert-sep-19-7-calls-sweep-60-near-the-ask-951--1249-vs-11-oi-ref809
Trevi Therapeutics Option Alert: Sep 19 $7...
08/27/2025 15:49:13

this-adient-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Adient Analyst Begins Coverage On A B...
08/21/2025 12:32:13

morgan-stanley-initiates-coverage-on-trevi-therapeutics-with-overweight-rating-announces-price-target-of-18
Morgan Stanley Initiates Coverage On Trevi...
08/21/2025 11:16:06

Morgan Stanley analyst Judah Frommer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and ann...

lisa-delfini-to-resign-as-cfo-of-trevi-therapeutics-on-aug-22--jennifer-l-good-to-serve-as-interim-principal-financial-officer
Lisa Delfini To Resign As CFO Of Trevi The...
08/20/2025 20:35:29

-SEC Filing

raymond-james-maintains-strong-buy-on-trevi-therapeutics-lowers-price-target-to-27
Raymond James Maintains Strong Buy on Trev...
08/08/2025 16:16:28

Raymond James analyst Ryan Deschner maintains Trevi Therapeutics (NASDAQ:TRVI) with a Strong Buy and lowers the price target...

needham-maintains-buy-on-trevi-therapeutics-lowers-price-target-to-22
Needham Maintains Buy on Trevi Therapeutic...
08/08/2025 11:32:25

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to...

trevi-therapeutics-q2-eps-009-beats-010-estimate
Trevi Therapeutics Q2 EPS $(0.09) Beats $(...
08/07/2025 20:06:27

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

cantor-fitzgerald-initiates-coverage-on-trevi-therapeutics-with-overweight-rating-announces-price-target-of-25
Cantor Fitzgerald Initiates Coverage On Tr...
07/01/2025 13:44:56

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and ...

reported-earlier-trevi-therapeutics-prices-100m-public-offering-of-174m-common-shares-at-575share
Reported Earlier, Trevi Therapeutics Price...
06/04/2025 05:57:31

dow-gains-over-100-points-us-job-openings-increase-in-april
Dow Gains Over 100 Points; US Job Openings...
06/03/2025 16:16:27

trevi-therapeutics-launches-100m-public-offering-of-common-stock-to-support-development-of-haduvio-for-chronic-cough-in-ipf-and-rcc
Trevi Therapeutics Launches $100M Public O...
06/02/2025 20:02:36

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduv...

trevi-therapeutics-showcases-drug-that-cuts-cough-frequency-in-lung-disease-patients
Trevi Therapeutics Showcases Drug That Cut...
06/02/2025 17:42:49

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...

d-boral-capital-maintains-buy-on-trevi-therapeutics-maintains-21-price-target
D. Boral Capital Maintains Buy on Trevi Th...
06/02/2025 11:54:26

D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.

trevis-cough-drug-haduvio-shows-results-in-ipf-patients-cutting-coughs-by-over-60
Trevi's Cough Drug Haduvio Shows Results i...
06/02/2025 11:12:02

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduv...

hc-wainwright--co-initiates-coverage-on-trevi-therapeutics-with-buy-rating-announces-price-target-of-21
HC Wainwright & Co. Initiates Coverage On ...
05/28/2025 10:39:57

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and ...

needham-reiterates-buy-on-trevi-therapeutics-maintains-24-price-target
Needham Reiterates Buy on Trevi Therapeuti...
05/20/2025 12:04:17

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $24 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION